ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve equity plan increase at 2026 annual meeting

ABVC BIOPHARMA, INC.

All 11 incumbent directors re-elected with overwhelming support (over 98% for each nominee).
Ratification of Simon & Edward, LLP as independent auditor for FY 2026: 10,597,352 for, 12,291 against.
Equity incentive plan increase approved: 9,964,400 for, 643,419 against; shares reserved now 15% of outstanding.
Quorum established with 10,612,493 shares (41.74% of voting power) present.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.